ALBANY — Curia announced Thursday that it would expand the pharmaceutical manufacturing capacity at its Rensselaer facility.
The Albany-based contract R&D and manufacturing firm, known until recently as AMRI, said the move would give it greater ability to fill both small-scale and large-volume orders for active pharmaceutical ingredients, or APIs.
Curia said the investment to make all this possible will run about $35 million and result in creation of new technical jobs. The project is expected to take 18 months to complete.
“Some of the life-saving products produced at Rensselaer are highly complex, including critical oncology therapeutics and novel treatments addressing unmet medical needs,” Curia Chairman and CEO John Ratliff said in a news release. “The engineering and technology advances we have designed for the site will enhance our flexibility, efficiency and scale, allowing us to meet our customers’ current and future complex manufacturing needs.”
The site currently produces components for more than 50 products.
Cura has 3,400 employees at 23 sites across the United States, Europe and Asia, including other API manufacturing facilities in the United States, France, Spain, Italy and India.